Skip to main content
SpringerLink
Log in
Book cover

Multimodality Management of Borderline Resectable Pancreatic Cancer pp 143–157Cite as

Assessment of Response to Preoperative Therapy

  • Chapter

  • 860 Accesses

Abstract

Assessment of response to preoperative therapy in borderline and locally advanced pancreatic cancer is a prerequisite for patient selection, surgical decision-making, clinical trial conduct, analysis, and comparison. Despite multiple studies on neoadjuvant treatment, universally accepted response measures are lacking as are clear definitions, standardized diagnostic work-up, and harmonization of classifications. Multiple different outcome measures have been proposed for response assessment including radiological criteria, pathologic response measures, surgical resection rates, and survival parameters. Unfortunately, studies have revealed marked differences between these endpoints preventing meaningful interpretation of data. In addition, inherent properties of pancreatic cancer like a pronounced desmoplastic stroma reaction impede response evaluation similar to the other solid tumors. All response measures proposed so far are prone to bias as long as patient selection, diagnostic evaluation, treatment regimes, restaging time points, pathologic work-up, and clinical follow-up are non-standardized. Therefore, standardized trials are needed to rigorously evaluate clinical and prognostic-relevant response endpoints. Furthermore, as neoadjuvant treatment regimes can lead to disease progression, toxicity, and clinical deterioration, a set of measures are needed to fully elucidate the radiologic, pathologic, and clinical response to neoadjuvant treatment. Given the current lack of evidence-based response measures, all borderline resectable pancreatic cancer patients are recommended to undergo surgical exploration at a specialized center following neoadjuvant therapy. For locally advanced unresectable patients, a specialized multidisciplinary team should define those patients in whom surgical exploration and resectability seems promising.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  2. Cancer Research UK . UK cancer mortality statistics for males [Internet]. http://info.cancerresearchuk.org/cancerstats/mortality/males/?a=5441. Accessed 16 Dec 2008.

  3. Cancer Research UK . UK cancer mortality statistics for females [Internet]. http://info.cancerresearchuk.org/cancerstats/mortality/females/?a=5441. Accessed 16 Dec 2008.

  4. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg. 1995;82(1):111–5.

    Article  CAS  PubMed  Google Scholar 

  5. Hedberg M, Borgström A, Genell S, Janzon L. Survival following pancreatic carcinoma: a follow-up study of all cases recorded in Malmö, Sweden, 1977-1991. Br J Surg. 1998;85(12):1641–4.

    Article  CAS  PubMed  Google Scholar 

  6. National Cancer Institute. SEER data, 1973-2011 [Internet]. http://seer.cancer.gov/data/. Accessed 15 Jan 2008.

  7. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27(11):1806–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Takahashi S, Kinoshita T, Konishi M, Gotohda N, Kato Y, Kinoshita T, et al. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci. 2011;18(4):567–74.

    Article  PubMed  Google Scholar 

  9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology—pancreatic adenocarcinoma [Internet]. [cited 2015 Jan 25]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed 15 Jan 2008.

  10. Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977–88.

    Article  PubMed  Google Scholar 

  11. Loizou L, Albiin N, Ansorge C, Andersson M, Segersvärd R, Leidner B, et al. Computed tomography staging of pancreatic cancer: a validation study addressing interobserver agreement. Pancreatology. 2013;13(6):570–5.

    Article  CAS  PubMed  Google Scholar 

  12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.

    Article  CAS  PubMed  Google Scholar 

  13. Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267.

    Google Scholar 

  14. Katz MHG, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95.

    Article  PubMed  Google Scholar 

  15. Katz MHG, Fleming JB, Bhosale P, Varadhachary G, Lee JE, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118(23):5749–56.

    Article  PubMed  Google Scholar 

  16. Festa V, Andriulli A, Valvano MR, Uomo G, Perri F, Andriulli N, et al. Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. JOP. 2013;14(6):618–25.

    PubMed  Google Scholar 

  17. Dudeja V, Greeno EW, Walker SP, Jensen EH. Neoadjuvant chemoradiotherapy for locally advanced pancreas cancer rarely leads to radiological evidence of tumour regression. HPB (Oxford). 2013;15(9):661–7.

    Article  Google Scholar 

  18. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.

    Article  CAS  PubMed  Google Scholar 

  19. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.

    Article  Google Scholar 

  20. Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7.

    Article  PubMed  Google Scholar 

  21. Krishnamoorthy SK, Jambawaliker S, Saif MW. Positron emission tomography imaging of pancreatic cancer. JOP. 2014;15(2):124–7.

    PubMed  Google Scholar 

  22. Varadhachary GR, Evans DB. Rational study endpoint(s) for preoperative trials in pancreatic cancer: pathologic response rate, margin negative resection, overall survival or “all of the above”? Ann Surg Oncol. 2013;20(12):3712–4.

    Article  PubMed  Google Scholar 

  23. Liebl F, Demir IE, Mayer K, Schuster T, DʼHaese JG, Becker K, et al. The impact of neural invasion severity in gastrointestinal malignancies: a clinicopathological study. Ann Surg. 2014;260(5):900–7; discussion 907–8.

    Article  PubMed  Google Scholar 

  24. Bockhorn M, Burdelski C, Bogoevski D, Sgourakis G, Yekebas EF, Izbicki JR. Arterial en bloc resection for pancreatic carcinoma. Br J Surg. 2011;98(1):86–92.

    Article  CAS  PubMed  Google Scholar 

  25. Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. Ann Oncol. 2013;10:mdt239.

    Google Scholar 

  26. Yekebas EF, Bogoevski D, Cataldegirmen G, Kunze C, Marx A, Vashist YK, et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg. 2008;247(2):300–9.

    Article  PubMed  Google Scholar 

  27. Nakayama Y, Yamashita Y, Kadota M, Takahashi M, Kanemitsu K, Hiraoka T, et al. Vascular encasement by pancreatic cancer: correlation of CT findings with surgical and pathologic results. J Comput Assist Tomogr. 2001;25(3):337–42.

    Article  CAS  PubMed  Google Scholar 

  28. Li H, Zeng MS, Zhou KR, Jin DY, Lou WH. Pancreatic adenocarcinoma: the different CT criteria for peripancreatic major arterial and venous invasion. J Comput Assist Tomogr. 2005;29(2):170–5.

    Article  PubMed  Google Scholar 

  29. Wong JC, Lu DSK. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008;6(12):1301–8.

    Article  PubMed  Google Scholar 

  30. Erkan M, Hausmann S, Michalski CW, Fingerle AA, Dobritz M, Kleeff J, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol. 2012;9(8):454–67.

    Article  CAS  PubMed  Google Scholar 

  31. Bittoni A, Santoni M, Lanese A, Pellei C, Andrikou K, Stefano C. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. [Review]. Gastroenterol Res Pract. 2014;2014:183852.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Laurence JM, Tran PD, Morarji K, Eslick GD, Lam VWT, Sandroussi C. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg. 2011;15(11):2059–69.

    Article  PubMed  Google Scholar 

  33. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5(2):121–30.

    Article  CAS  PubMed  Google Scholar 

  34. Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150(3):466–73.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19(5):1644–62.

    Article  PubMed  Google Scholar 

  36. Kelly KJ, Winslow E, Kooby D, Lad NL, Parikh AA, Scoggins CR, et al. Vein involvement during pancreaticoduodenectomy: is there a need for redefinition of “borderline resectable disease”? J Gastrointest Surg. 2013;17(7):1209–17; discussion 1217.

    Article  PubMed  Google Scholar 

  37. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JHG, Bakkevold KE, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg. 2008;143(1):75–83; discussion 83.

    Article  PubMed  Google Scholar 

  38. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232–7.

    Article  CAS  PubMed  Google Scholar 

  39. Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651–60.

    Article  PubMed  Google Scholar 

  40. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199–210; discussion 1210–1.

    Article  PubMed  Google Scholar 

  41. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;244(1):10–5.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Kuhlmann KFD, de Castro SMM, Wesseling JG, ten Kate FJW, Offerhaus GJA, Busch ORC, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40(4):549–58.

    Article  CAS  PubMed  Google Scholar 

  43. Han S-S, Jang J-Y, Kim S-W, Kim W-H, Lee KU, Park Y-H. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas. 2006;32(3):271–5.

    Article  PubMed  Google Scholar 

  44. Cleary SP, Gryfe R, Guindi M, Greig P, Smith L, Mackenzie R, et al. Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg. 2004;198(5):722–31.

    Article  PubMed  Google Scholar 

  45. Connor S, Bosonnet L, Ghaneh P, Alexakis N, Hartley M, Campbell F, et al. Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status. Br J Surg. 2004;91(12):1592–9.

    Article  CAS  PubMed  Google Scholar 

  46. Tseng JF, Raut CP, Lee JE, Pisters PWT, Vauthey J-N, Abdalla EK, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8(8):935–49; discussion 949–50.

    Article  PubMed  Google Scholar 

  47. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 1993;165(1):68–72; discussion 72–3.

    Article  CAS  PubMed  Google Scholar 

  48. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, et al. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg. 2001;234(6):758–68.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. Hoboken: Wiley; 2010. p. 336.

    Google Scholar 

  50. Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009;11(1):18–24.

    Article  Google Scholar 

  51. Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52–60.

    Article  PubMed Central  PubMed  Google Scholar 

  52. Chatterjee D, Katz MH, Rashid A, Varadhachary GR, Wolff RA, Wang H, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012;118(12):3182–90.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  54. Estrella JS, Rashid A, Fleming JB, Katz MH, Lee JE, Wolf RA, et al. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012;118(1):268–77.

    Article  PubMed  Google Scholar 

  55. Zhao Q, Rashid A, Gong Y, Katz MH, Lee JE, Wolf R, et al. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol. 2012;16(1):29–37.

    Article  CAS  PubMed  Google Scholar 

  56. Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, et al. Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol. 2011;18(13):3601–7.

    Article  PubMed  Google Scholar 

  57. Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253(5):934–9.

    Google Scholar 

  58. Ishikawa O, Ohhigashi H, Sasaki Y, Imaoka S, Iwanaga T, Teshima T, et al. The histopathological effect of preoperative irradiation in adenocarcinoma of the periampullary region. Nihon Gan Chiryo Gakkai Shi. 1988;23(3):720–7.

    CAS  PubMed  Google Scholar 

  59. Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Compton CC, et al. Protocol for the examination of specimens from patients with carcinoma of the perihilar bile ducts. Arch Pathol Lab Med. 2010;134(4):e19–24.

    PubMed  Google Scholar 

  60. Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335–9.

    Article  CAS  PubMed  Google Scholar 

  61. White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, et al. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12(3):214–21.

    Article  PubMed  Google Scholar 

  62. Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20(7):2188–96.

    Article  PubMed  Google Scholar 

  63. Boone BA, Steve J, Zenati MS, Hogg ME, Singhi AD, Bartlett DL, et al. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol. 2014;21(13):4351–8.

    Article  PubMed  Google Scholar 

  64. Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. J Surg Oncol. 2011;104(2):155–61.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Motoi F, Ishida K, Fujishima F, Ottomo S, Oikawa M, Okada T, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial. Ann Surg Oncol. 2013;20(12):3794–801.

    Article  PubMed  Google Scholar 

  66. Tzeng C-WD, Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16(5):430–8.

    Article  PubMed Central  Google Scholar 

  67. Balachandran A, Ahmad M, Lee JE, Krishnan S, Wang H, Crane CH, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB. 2014;16(5):430–8.

    Article  PubMed Central  PubMed  Google Scholar 

  68. Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109(4):926–33.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  69. Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, et al. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2014;89(4):830–8.

    Article  CAS  PubMed  Google Scholar 

  70. Katz MHG, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PWT, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17(7):1794–801.

    Article  PubMed Central  PubMed  Google Scholar 

  71. FDA. Guidance for industry clinical trail endpoints the approval of cancer drugs and biologics. 2007.

    Google Scholar 

  72. EMEA. Guideline on the evaluation of anticancer medicinal products in man. 2012.

    Google Scholar 

  73. Assfalg V, Michalski CW, Gillen S, Kleeff J, Friess H. Unresectable pancreatic cancer—palliative interventional and surgical treatment. [Review German]. Zentralbl Chir. 2010;135(6):502–7.

    Article  PubMed  Google Scholar 

  74. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v4.03 [Internet]. 2010. http://evs.nci.nih.gov/ftp1/CTCAE/About.html

  75. Schäfer M, Müllhaupt B, Clavien P-A. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg. 2002;236(2):137–48.

    Article  PubMed Central  PubMed  Google Scholar 

  76. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8–13.

    Article  PubMed  Google Scholar 

  77. Wente MN, Veit JA, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, et al. Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery. 2007;142(1):20–5.

    Article  PubMed  Google Scholar 

  78. Wente MN, Bassi C, Dervenis C, Fingerhut A, Gouma DJ, Izbicki JR, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2007;142(5):761–8.

    Article  PubMed  Google Scholar 

  79. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.

    Article  PubMed  Google Scholar 

  80. Katz MHG, Pisters PWT, Evans DB, Sun CC, Lee JE, Fleming JB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206(5):833–46; discussion 846–8.

    Article  PubMed  Google Scholar 

  81. La Torre M, Nigri G, Cavallini M, Mercantini P, Ziparo V, Ramacciato G. The Glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2012;19(9):2917–23.

    Article  PubMed  Google Scholar 

  82. Jamieson NB, Denley SM, Logue J, MacKenzie DJ, Foulis AK, Dickson EJ, et al. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2011;18(8):2318–28.

    Article  PubMed  Google Scholar 

  83. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40.

    Article  PubMed  Google Scholar 

  84. Wang D, Luo H, Qiu M, Wang Z, Zhang D, Wang F, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012;29(5):3092–100.

    Article  CAS  PubMed  Google Scholar 

  85. Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 2013;109(2):416–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. AJCC. AJCC cancer staging manual [Internet]. http://www.springer.com/medicine/surgery/book/978-0-387-88440-0. Accessed 25 Jan 2015.

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Ismaninger Strasse 22, Munich, 81675, Germany

    André L. Mihaljevic M.D., M.Sc. & Jörg Kleeff M.D., F.A.C.S.

Authors
  1. André L. Mihaljevic M.D., M.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jörg Kleeff M.D., F.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörg Kleeff M.D., F.A.C.S. .

Editor information

Editors and Affiliations

  1. Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas, USA

    Matthew H.G. Katz

  2. Division of Surgical Oncology, The University of Cincinnati Medical Center, Cincinnati, Ohio, USA

    Syed A. Ahmad

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mihaljevic, A.L., Kleeff, J. (2016). Assessment of Response to Preoperative Therapy. In: Katz, M., Ahmad, S. (eds) Multimodality Management of Borderline Resectable Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22780-1_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22780-1_9

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22779-5

  • Online ISBN: 978-3-319-22780-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation